2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-181445
    NSC 620023 TFA
    NSC 620023 TFA is a highly selective butyrylcholinesterase (BChE) inhibitor with an IC50 of 32 nM. NSC 620023 TFA acts via π-stacking interactions with dual benzimidazole moieties and hydrophobic interactions within the BChE binding site. NSC 620023 TFA can be used for the research of alzheimer’s disease.
    NSC 620023 TFA
  • HY-181448
    Phytic acid hexalithium 98%
    Phytic acid (Inositol hexaphosphate hexalithium) hexalithium is an orally active compound. Phytic acid hexalithium can be derived from the seeds of legumes. Phytic acid is a [PO4]3- storage depot and precursor for other inositol phosphates and pyrophosphates. Phytic acid hexalithium attenuates Aβ oligomers and upregulates Autophagy protein. Phytic acid hexalithium can be used in cardiovascular disease, metabolic disease, nervous system disease and cancer research.
    Phytic acid hexalithium
  • HY-181482
    A1480LS 98%
    A1480LS is a peripherally restricted, orally active covalent and irreversible inhibitor of DAGLα and DAGLβ, with IC50 values of 6 nM and 4 nM against human targets, respectively, and IC50 values ≤15 nM across mouse, rat, dog, monkey and human systems. A1480LS reduces the levels of 2-arachidonoylglycerol, arachidonic acid, and cyclooxygenase- and lipoxygenase-derived eicosanoids. A1480LS inhibits injury-induced production of 2-arachidonoylglycerol and arachidonic acid in the peripheral sciatic nerve, and suppresses the responses of high-threshold and wide-dynamic-range-like dorsal horn neurons to mechanical stimulation. A1480LS alleviates pain behaviors in rat models of inflammatory pain, neuropathic pain and chemotherapy-induced peripheral neuropathy.
    A1480LS
  • HY-181503
    AChE/BuChE-IN-8
    AChE/BuChE-IN-8 is a dual AChE and BuChE inhibitor, with an AChE IC50 of 1.18 μM, a human AChE Ki of 1.2 μM, and a BuChE IC50 of 2.34 μM. AChE/BuChE-IN-8 acts as an antiproliferative agent and antioxidant, exerts antiproliferative effects on colon cancer cells, scavenges free radicals, and exhibits reducing power. AChE/BuChE-IN-8 can be used in the research of Alzheimer's disease and colorectal adenocarcinoma.
    AChE/BuChE-IN-8
  • HY-181515
    KOR agonist 8
    KOR agonist 8 (Compound 8a) is a κ-opioid receptor (KOR) agonist and an analgesic agent, with a Ki value of 5.3 nM for human KOR, and EC50 values of 43.1 nM and 9236 nM for human KOR. It exhibits subtype selectivity for MOR/KOR and DOR/KOR. KOR agonist 8 is applicable for pain-related research.
    KOR agonist 8
  • HY-181543
    CVN14 2925663-26-7
    CVN14 is a potent, selective and brain-penetrant CD38 inhibitor with human IC50 19 nM, mouse IC50 2.4 nM. CVN14 binds uncompetitively to form a complex with CD38 and ADPR, and inhibits CD38 enzymatic activity. CVN14 can be used for the research of neurodegenerative diseases.
    CVN14
  • HY-181549
    PDE4-IN-32 3080627-61-5
    PDE4-IN-32 (Compound B05) is a selective, blood-brain barrier permeable PDE4B and PDE4D inhibitor with IC50 values of 13.7 nM and 23.8 nM, respectively. PDE4-IN-32 promotes the recovery of motor and cognitive function in MCAO/R mouse models. PDE4-IN-32 reduces cerebral edema. PDE4-IN-32 can be used for the research of ischemic stroke.
    PDE4-IN-32
  • HY-181552
    GABAA receptor modulator-13
    GABAA receptor modulator-13 is an orally active, blood-brain barrier-permeable α4β1δ GABAA receptor modulator (IC50 = 9.02 μM). GABAA receptor modulator-13 reduces GABA-induced currents, impairs the stability of the transmembrane domain M2-M3 loop of α4β1δ GABAA receptors, and exhibits selectivity for γ2-containing GABAA receptor subtypes and α6β3δ GABAA receptor subtypes. GABAA receptor modulator-13 is applicable to the research of nervous system diseases with altered tonic inhibition, such as neurodevelopmental disorders and epilepsy.
    GABAA receptor modulator-13
  • HY-181573
    TC8026 98%
    TC8026 is an allosteric-covalent inhibitor targeting protein disulfide isomerase (PDI), with an IC50 of 7 μM against human PDI. TC8026 induces endoplasmic reticulum stress-mediated apoptosis. TC8026 is a hit compound with PDI inhibitory activity identified via high-throughput screening, and it can be used for the research of glioblastoma.
    TC8026
  • HY-181574
    PDI-IN-5 3097563-91-9
    PDI-IN-5 (compound 30z) is an allosteric-covalent inhibitor targeting protein disulfide isomerase (PDI) with a 2-chloro-pyrrolopyrimidin-4-one scaffold, with an IC50 of 0.4 μM. PDI-IN-5 exhibits selectivity for ERp57 and GPX4, and inhibits glioblastoma. PDI-IN-5 can be used in glioblastoma-related research.
    PDI-IN-5
  • HY-181575
    TPH2 agonist-1 98%
    TPH2 agonist-1 (compound 20e) is an orally active, blood-brain barrier permeable, 1,3,4-oxadiazol-2 (3H)-one-derived TPH2 agonist. TPH2 agonist-1 upregulates TPH2 expression, elevates 5-HT and GABA levels, and exhibits antiepileptic activity in SCN1A-deficient models. TPH2 agonist-1 stabilizes the electrophysiological activity of neuronal networks and inhibits abnormal spike and burst activities. TPH2 agonist-1 shows no significant hERG inhibition or cytotoxicity, and it can be used in studies related to severe myoclonic epilepsy of infancy (Dravet syndrome).
    TPH2 agonist-1
  • HY-181589
    PDE11A4-IN-2 98%
    PDE11A4-IN-2 is a selective PDE11A4 inhibitor with an IC50 of 33 nM. PDE11A4-IN-2 functionally inhibits PDE11A4-mediated catalytic activities of cAMP and cGMP in cellular models. PDE11A4-IN-2 is applicable to the research of age-related cognitive decline.
    PDE11A4-IN-2
  • HY-181597
    LINS05414
    LINS05414 is a histamine H3 receptor ligand with antiCholinesterase and metal chelating activities. LINS05414 exhibits inhibitory activity against acetylcholinesterase (pIC50 = 4.03) and butyrylcholinesterase (pIC50 = 3.83), with a pKi of 6.37 for human histamine H3 receptors. LINS05414 chelates copper ions, ferrous ions and ferric ions. LINS05414 regulates the release of neurotransmitters. LINS05414 can be used in the research of neurodegenerative diseases.
    LINS05414
  • HY-181605
    MOR antagonist 2 hydrochloride 3075862-29-9 98%
    MOR antagonist 2 hydrochloride is a blood-brain barrier-permeable μ-opioid receptor (MOR) antagonist, with an IC50 of 28.37 nM, an EC50 of 4.25 nM, and a Ki of 0.18 nM against MOR. MOR antagonist 2 hydrochloride stabilizes the inactive conformation of MOR to reduce receptor activation levels. MOR antagonist 2 hydrochloride antagonizes analgesic effects in the mouse warm-water tail-flick test. MOR antagonist 2 hydrochloride induces fewer opioid withdrawal symptoms (wet dog shakes, paw tremors) in mice with opioid withdrawal symptoms. MOR antagonist 2 hydrochloride can be used for the research of opioid use disorder.
    MOR antagonist 2 hydrochloride
  • HY-181606
    Cyclo(phg-isoDGR-k)-PEG4-non-cleavable-SAR405838
    Cyclo (phg-isoDGR-k)-PEG4-non-cleavable-SAR405838 is a dual MDM2 and α5β1 integrin modulator. Cyclo (phg-isoDGR-k)-PEG4-non-cleavable-SAR405838 acts as an antiproliferative agent, apoptosis inducer and cell cycle regulator, induces reactivation of p53 and upregulation of p21, redistributes glioblastoma cells from the G0/G1 phase to the G2/M phase, and enhances apoptosis. Cyclo (phg-isoDGR-k)-PEG4-non-cleavable-SAR405838 is applicable to the research of glioblastoma.
    Cyclo(phg-isoDGR-k)-PEG4-non-cleavable-SAR405838
  • HY-181612
    COX-2/CaV2.2-IN-1 98%
    COX-2/CaV2.2-IN-1 is an orally active and selective dual COX-2/CaV2.2 inhibitor, exhibiting a COX-2 IC50 of 0.26 μM and a CaV2.2 IC50 of 0.29 μM. COX-2/CaV2.2-IN-1 suppresses inflammatory responses and inflammatory mediator (IL-6, TNF-α, NO) production. COX-2/CaV2.2-IN-1 produces pronounced analgesic effects in diverse models of inflammatory, neuropathic, and visceral pain. COX-2/CaV2.2-IN-1 can be used for the research of chronic pain.
    COX-2/CaV2.2-IN-1
  • HY-181613
    5-HT2A&5-HT2C agonist-3 3082429-35-1 98%
    5-HT2A&5-HT2C agonist-3 is an orally active and blood-brain barrier penetrant 5-HT2A and 5-HT2C agonist, with pEC50 values of 7.79 and 7.10, respectively. 5-HT2A&5-HT2C agonist-3 elevates intracellular calcium levels in cells overexpressing 5-HT2A or 5-HT2C receptors, and shows no activity against 5-HT2B receptors. 5-HT2A&5-HT2C agonist-3 can be used in the research of neuropsychiatric disorders.
    5-HT2A&5-HT2C agonist-3
  • HY-181621
    Tmem175 modulator 2 98%
    Tmem175 modulator 2 (example 180) is a TMEM175 modulator.Tmem175 modulator 2 can be used for the research of neurodegenerative disorders.
    Tmem175 modulator 2
  • HY-181622
    TMEM175 modulator 3 3115239-67-0 98%
    TMEM175 modulator 3 (Compound 14) is a TMEM175 modulator. TMEM175 modulator 3 can be used in research on neurodegenerative diseases.
    TMEM175 modulator 3
  • HY-181636
    VU6077967
    VU6077967 is a selective cannabinoid receptor 2 (CB2) agonist with an EC50 of 8.6 nM for rCB2. VU6077967 can be used for the research of neurological disease, suah as Alzheimer’s disease.
    VU6077967
Cat. No. Product Name / Synonyms Application Reactivity